Haleos Labs Limited
Bombay Stock ExchangeTotal Valuation
Haleos Labs Limited carries a market capitalization of 4.72B, placing it among publicly traded companies globally. Its enterprise value stands at 3.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.72B |
| Enterprise Value | 3.69B |
Valuation Ratios
Haleos Labs Limited trades at a trailing price-to-earnings ratio of 21.34.
| PE Ratio | 21.34 |
| PS Ratio | 1.13 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Haleos Labs Limited trades at an EV/EBITDA multiple of 14.51 and an EV/FCF ratio of 65.59. The EV/Sales ratio of 1.13 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.51 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.13 |
| EV / EBITDA | 14.51 |
| EV / EBIT | 14.51 |
| EV / FCF | 65.59 |
Financial Position
Haleos Labs Limited maintains a current ratio of 2.13, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 86.10, indicating elevated leverage, while an interest coverage ratio of 3.21 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.13 |
| Quick Ratio | 0.02 |
| Debt / Equity | 86.10 |
| Debt / EBITDA | N/A |
| Interest Coverage | 3.21 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 25.51 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Haleos Labs Limited has paid 65.52M in income taxes, reflecting an effective tax rate of 29.03.
| Income Tax | 65.52M |
| Effective Tax Rate | 29.03 |
Stock Price Statistics
Haleos Labs Limited's stock has gained approximately 30.3614% over the past 52 weeks. The 50-day moving average sits at 1,217.31, while the 200-day moving average is 1,210.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | 30.3614% |
| 50-Day Moving Average | 1,217.31 |
| 200-Day Moving Average | 1,210.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Haleos Labs Limited generated 3.27B in revenue and converted that into 172.68M in net income, yielding earnings per share of 52.99. EBITDA reached 253.98M, while operating income came in at 253.98M.
| Revenue | 3.27B |
| Gross Profit | 1.15B |
| Operating Income | 253.98M |
| Pretax Income | 225.70M |
| Net Income | 172.68M |
| EBITDA | 253.98M |
| EBIT | 253.98M |
| Earnings Per Share (EPS) | 52.99 |
Margins
Haleos Labs Limited operates with a gross margin of 35.24, reflecting its pricing power and cost economics. The operating margin of 7.77 and net profit margin of 5.28 provide insight into operational efficiency.
| Gross Margin | 35.24 |
| Operating Margin | 7.77 |
| Pretax Margin | 6.91 |
| Profit Margin | 5.28 |
| EBITDA Margin | 7.77 |
Scores
Haleos Labs Limited posts an Altman Z-Score of 4.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.11 |